Introduction: Navigating the Clinical Dilemma of Benzodiazepine Use in Pregnancy
The management of anxiety and sleep disorders during pregnancy presents a complex clinical challenge. Benzodiazepines (BZDs) are frequently prescribed to manage these conditions, yet their safety profile regarding pregnancy outcomes has long been a subject of debate. Despite the clinical necessity in certain psychiatric presentations, the utilization of BZDs during pregnancy has increased globally. Prior observational studies have yielded conflicting results regarding the association between BZD exposure and adverse outcomes such as preterm birth (PTB), small for gestational age (SGA), and pregnancy loss. Many of these discrepancies stem from methodological biases, including confounding by indication and the failure to account for competing risks—where an event like an abortion prevents the occurrence of a later outcome like preterm birth. A recent study published in JAMA Internal Medicine addresses these gaps by employing a sophisticated target trial emulation design to clarify these risks.
